- Home
- IOVA vs SIGIP Comparison
IOVA vs SIGIP Comparison
Compare IOVA & SIGIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- SIGIP
- Stock Information
- Founded
- IOVA 2007
- SIGIP N/A
- Country
- IOVA United States
- SIGIP United States
- Employees
- IOVA N/A
- SIGIP 2800
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- SIGIP Property-Casualty Insurers
- Sector
- IOVA Health Care
- SIGIP Finance
- Exchange
- IOVA Nasdaq
- SIGIP Nasdaq
- Market Cap
- IOVA 1.0B
- SIGIP N/A
- IPO Year
- IOVA N/A
- SIGIP N/A
- Fundamental
- Price
- IOVA $3.56
- SIGIP $17.36
- Analyst Decision
- IOVA Strong Buy
- SIGIP
- Analyst Count
- IOVA 9
- SIGIP 0
- Target Price
- IOVA $18.22
- SIGIP N/A
- AVG Volume (30 Days)
- IOVA 9.8M
- SIGIP N/A
- Earning Date
- IOVA 05-08-2025
- SIGIP N/A
- Dividend Yield
- IOVA N/A
- SIGIP N/A
- EPS Growth
- IOVA N/A
- SIGIP N/A
- EPS
- IOVA N/A
- SIGIP N/A
- Revenue
- IOVA $164,070,000.00
- SIGIP N/A
- Revenue This Year
- IOVA $182.20
- SIGIP N/A
- Revenue Next Year
- IOVA $62.10
- SIGIP N/A
- P/E Ratio
- IOVA N/A
- SIGIP N/A
- Revenue Growth
- IOVA 13698.99
- SIGIP N/A
- 52 Week Low
- IOVA $2.70
- SIGIP N/A
- 52 Week High
- IOVA $14.23
- SIGIP N/A
- Technical
- Relative Strength Index (RSI)
- IOVA 52.93
- SIGIP 43.72
- Support Level
- IOVA $2.89
- SIGIP $17.17
- Resistance Level
- IOVA $3.43
- SIGIP $17.49
- Average True Range (ATR)
- IOVA 0.28
- SIGIP 0.26
- MACD
- IOVA 0.10
- SIGIP 0.03
- Stochastic Oscillator
- IOVA 89.13
- SIGIP 63.67
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About SIGIP Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, Investments. Majority of revenue is gained from Standard Personal Lines. Currently company has it's revenues from States of USA and Columbia.